Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis

Published:2019-02-01 Issue:2 Volume:54 Page:178-187
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Dignass Axel U.¹^ORCID,Siegmund Britta²,Goertz Ralf³^ORCID,Schneidewind Gundula⁴,Fanter Lena⁵^ORCID

Affiliation:

1. Department of Medicine I, Agaplesion Markus Hospital, Goethe-University, Frankfurt am Main, Germany;

2. Department of Medicine(Gastroenterology, Infectious Diseases, Rheumatology), Charité–Universitätsmedizin Berlin, Berlin, Germany;

3. AMS Advanced Medical Services GmbH, Mannheim, Germany;

4. Takeda Pharmaceuticals International AG, Zurich, Switzerland;

5. Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany

Funder

Takeda Pharmaceuticals International Co

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2019.1569124

Reference28 articles.

1. Ulcerative Colitis

2. Ulcerative Colitis Care Pathway

3. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey

4. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

5. Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Vedolizumab-Nutzenbewertung gemäß § 35a SGB V des G-BA

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn’s Disease and Ulcerative Colitis;Gastroenterology Research;2023-12

2. Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease;European Journal of Gastroenterology & Hepatology;2021-05-03

3. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis;Expert Review of Gastroenterology & Hepatology;2021-03-04

4. Anti-trafficking agents in the treatment of inflammatory bowel disease;Current Opinion in Gastroenterology;2019-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3